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Abstract
Background: CCAAT enhancer-binding protein (C/EBP)β regulates gene expression in multiple organ systems and cell
types, including astrocytes in the central nervous system (CNS). Inflammatory stimuli, interleukin (IL)-1β, tumor necrosis
factor-α, human immunodeficiency virus (HIV)-1 and lipopolysaccharide induce astrocyte C/EBPβ expression. C/EBPβ is
detectable in brains of Alzheimer’s disease (AD), Parkinson’s disease (PD) and HIV-1-associated dementia (HAD) patients,
yet little is known about how C/EBPβ contributes to astrocyte gene regulation during neuroinflammation.
Methods: The expression of 92 human inflammation genes was compared between IL-1β-treated primary human
astrocytes and astrocytes transfected with C/EBPβ-specific small interfering (si)RNA prior to IL-1β treatment for 12 h.
Transcripts altered by> two-fold compared to control were subjected to one-way analysis of variance and Newman-Keuls
post-test for multiple comparisons. Expression of two genes, cyclooxygenase-2 (COX-2) and bradykinin receptor B2
(BDKRB2) was further confirmed in additional human astrocyte donors. Astrocytes were treated with mitogen-activated
protein kinase-selective inhibitors, then with IL-1β for 12 or 24 h followed by COX-2 and BDKRB2, expression analyses.
Results: IL-1β altered expression of 29 of 92 human inflammation genes by at least two-fold in primary human
astrocytes in 12 h. C/EBPβ knockdown affected expression of 17 out of 29 IL-1β-regulated genes by> 25%. Two genes
relevant to neuroinflammation, COX-2 and BDKRB2, were robustly decreased and increased, respectively, in response to
C/EBPβ knockdown, and expression was confirmed in two additional donors. COX-2 and BDKRB2 mRNA remained altered
in siRNA-transfected astrocytes at 12, 24 or 72 h. Inhibiting p38 kinase (p38K) activation blocked IL-1β-induced astrocyte
COX-2 mRNA and protein expression, but not IL-1β-induced astrocyte BDKRB2 expression. Inhibiting extracellular-
regulated kinase (ERK)1/2 activation blocked IL-1β-induced BDKRB2 mRNA expression while increasing COX-2 expression.
Conclusion: These data support an essential role for IL-1β in the CNS and identify new C/EBPβ functions in astrocytes.
Additionally, this work suggests p38K and ERK1/2 pathways may regulate gene expression in a complementary manner
to fine tune the IL-1β-mediated astrocyte inflammatory response. Delineating a role for C/EBPβ and other involved
transcription factors in human astrocyte inflammatory response may lead to effective therapies for AD, PD, HAD and other
neurological disorders.
Keywords: Astrocyte, Interleukin-1β, C/EBPβ, ERK1/2, p38K
Background
Neuroinflammation is a contributing factor of many central
nervous system (CNS) pathologies; yet the details of onset
and progression remain enigmatic. Astrocytes, the most
numerous cells of the CNS, contribute to homeostasis in
the CNS, regulate neural signaling and maintain the blood–
brain barrier (BBB) [1–3]. Accordingly, astrocytes respond
to inflammatory stimuli by altering gene expression,
morphology and function. Activated astrocytes undergo
rapid replication, migrate to areas of insult and attempt to
mitigate collateral damage by isolating the damaged area
[4–6]. Previously, we reported that CCAAT enhancer-
binding protein (C/EBP)-β is expressed in the brains of
human immunodeficiency virus (HIV)-1-infected patients
and contributes to interleukin (IL)-1β-induced tissue inhibi-
tor metalloproteinases (TIMP)-1 expression in astrocytes
[7]. In a related study, we explored the signal transduction
pathways mediating IL-1β-induced astrocyte C/EBPβ and
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TIMP-1 expression [8]. We found that a p38 kinase
(p38K)-selective inhibitor blocked IL-1β-induced astrocyte
C/EBPβ expression, whereas an extracellular regulated
kinase (ERK) 1/2-selective inhibitor blocked IL-1β-
induced astrocyte TIMP-1 expression. In this report, we
explore the role of C/EBPβ in regulating IL-1β-induced
astrocyte inflammatory genes and the signal transduction
pathways involved.
C/EBPβ is evolutionarily conserved among species and is
expressed in multiple organ systems [9–11]. The gene is
expressed as a single transcript that can be translated into
three isoforms: 42 kilodalton (kDa), 40 kDa and 20 kDa
[12,13]. The two large isoforms, designated liver-activating
proteins, are named for their transcriptional activating
properties, while the 20-kDa liver-inhibiting protein is
named for its inhibitory properties [14]. It is now clear that
the isoform-specific divergent roles for C/EBPβ isoforms do
not completely explain their function [15,16]. In the CNS,
astrocytes and microglia increase C/EBPβ expression in
response to various inflammatory stimuli including IL-1β,
lipopolysaccharides, tumor necrosis factor (TNF)-α and
HIV-1 [7,17]. Since the discovery that C/EBPβ regulates IL-
6, studies have shown that it regulates nitric oxide synthase
(NOS)-2, complementary protein 3 and other important
genes [15,16,18–21]. These data suggest an important role
of this highly conserved transcription factor, but C/EBPβ
isoform-specific activity is contextual in regard to the tissue
microenvironment and cell type [15,16,19]. Given the ple-
thora of cell-type- and ligand-dependent outcomes of C/
EBPβ-mediated gene responses, a complete understanding
of neuroinflammation warrants elucidating C/EBPβ func-
tion in the human astrocyte inflammatory response. Our
group found that C/EBPβ is expressed in the brains of
HIV-1 patients and contributes to regulation of human
astrocyte TIMP-1 [7]. Overall, these data implicate C/EBPβ
activity during CNS pathologies, but the extent to which
the transcription factor regulates global astrocyte immune
responses is unknown.
It is well established that IL-1β mediates neuroinflamma-
tion through activation of glial cells and subsequent
changes in gene expression [1]. Following IL-1β-mediated
activation of glial cells, nuclear C/EBPβ levels increase and
affect gene transcription [7,17]. In this study, we profile the
role of C/EBPβ in regulating IL-1β-mediated expression of
92 inflammatory genes in primary human astrocytes. We
found that IL-1β altered expression of ~32% (29/92) mRNA
transcripts tested. Furthermore, C/EBPβ regulated 59% (17/
29) of these genes by increasing or decreasing transcript
levels. Because of their role in neuroinflammation, two
genes that were affected oppositely by C/EBPβ knockdown,
cyclooxygenase (COX)-2 and bradykinin receptor b2
(BDKRB2) were chosen for further studies. ERK1/2 and
p38K pathway-selective inhibitors also exhibited opposite
effects on IL-1β-induced astrocyte COX-2 and BDKRB2
expression. These data illustrate the complexity of the IL-
1β-mediated astrocyte inflammatory response and provide
details of the regulatory mechanisms involved.
Experimental procedures
Isolation, cultivation and activation of human astrocytes
Human astrocytes were isolated from first- and early
second-trimester (gestational weeks 12–18) aborted spe-
cimens obtained from the Birth Defects Laboratory,
University of Washington, Seattle, in full compliance
with the ethical guidelines of the NIH, the Universities
of Washington and North Texas Health Science Center.
The Birth Defects Laboratory is an NIH-funded institu-
tion with the mission of disseminating tissues for the ad-
vancement of biomedical research. Astrocytes were
isolated from specimens as originally described earlier
[22]. Activation of astrocytes was achieved by applying
IL-1β for various time intervals. IL-1β is a prototypical
inflammatory cytokine expressed during HIV-1 CNS in-
fection, making IL-1β an excellent choice for studying
human astrocyte function during neuroinflammation
[23]. We empirically tested IL-1β dosage and transfec-
tion of astrocytes with C/EBPβ small interfering (si)RNA
as described in Fields et al. [7]. Accordingly, these data
provide relevant implications for astrocyte function in
many pathologies involving neuroinflammation.
RNA isolation and TaqManW human inflammation array
and real-time reverse transcription polymerase chain
reaction (RT2PCR)
Astrocytes were transfected with nonspecific control
(siCON) or C/EBPβ-specific (siC/EBPβ) siRNA by nucleo-
fection and then cultured as adherent monolayers in
75 cm2 flasks at a density of 8× 106 cells per flask or six-
well plates at a density of 1.6× 106 cells per well for 24 h.
The following day, the medium was exchanged with or
without IL-1β (20 ng/ml) for 24 h. Alternatively, astrocytes
were cultured in six-well plates at a density of 1.6× 106 cells
per well for 24 h, and then the medium was exchanged
with or without MAPK-selective inhibitors (SB203580-
sc222296 and U0126-sc202374, Santa Cruz Biotechnology,
Santa Cruz, CA) for 1 h and then with inhibitor plus IL-1β
(20 ng/ml) for 12 h. Astrocyte RNA was extracted (RNeasy
plus mini kit, Qiagen, Alameda, CA) and reverse-
transcribed into cDNA as per the manufacturer’s instruc-
tions (High Capacity cDNA Reverse Transcription Kit, Life
Technologies Corp., Carlsbad, CA). The TaqManW Human
Inflammation Array (Life Techologies, C/N: 4414074) was
used to assay for expression of 92 inflammation genes using
total RNA from two independent human astrocyte donors
(Figure 1). Data are illustrated in Figure 1 as a heat map;
red and green represent positive and negative fold change,
respectively. Increasing color intensity corresponds to in-
creasing absolute value. Orange and blue represent positive
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and negative percent change, respectively, in target MRNA
levels in siC/EBPβ+ IL-1β versus IL-1β conditions. Read-
outs from each TaqManW assay target were independently
analyzed comparing control, IL-1β and siC/EBPβ+ IL-1β
by one-way analysis of variance (ANOVA) followed by
Newman-Keuls post-test. Selected targets were confirmed
individually by RT2PCR TaqManW gene expression assays
performed using the StepOnePlus sequence-detection sys-
tem (Life Techologies), using primers specific to C/EBPβ
(C/N: Hs00270923_m1), COX-2 (C/N: Hs00153133_m1),
BDKRB2 (C/N: Hs00176121_m1) and glyceraldehyde phos-
phate dehydrogenase (GAPDH, C/N: 4310859]. The reac-
tions were carried out at 48 °C for 30 min and 95 °C for
10 min, followed by 40 cycles of 95 °C for 15 s and 60 °C
for 1 min. Samples were analyzed in triplicate. Fold
changes were calculated using the comparative CT
method [24]. One-way ANOVA followed by Newman-
Keuls post-test was used to analyze RT2PCR data.
Figure 1 IL-1β regulates expression of 29 of 92 human inflammation genes; C/EBPβ knockdown affects 17 of the 29 genes. Primary
human astrocytes, from two independent donors, were transfected with siCON or siC/EBPβ, cultured for 24 h and then treated with IL-1β (20 ng/
ml) for 12 h. Total RNA was isolated, reverse-transcribed and then assayed for human inflammation gene expression using the TaqManW Human
Inflammation Assay. Data are illustrated as a heat map; red and green represent positive and negative fold-change, respectively. Increasing color
contrast corresponds to increasing absolute fold-change. Orange and blue represent positive and negative percent change, respectively, in target
mRNA levels in Emphasis>/Emphasis>/EBPβ+ IL-1β versus IL-1β. Each individual TaqManW assay of the Human Inflammation Array was
independently analyzed by one-way ANOVA followed by Newman-Keuls post-test to compare among control, IL-1β and Emphasis>/Emphasis>/
EBPβ treatments. Significance was set at p< 0.05. (Newman-Keuls post-test: control versus IL-1β, * = p< 0.05; control versus siC/EBPβ+ IL-1β,
^ = p< 0.05; siC/EBPβ + IL-1β versus IL-1β, # = p< 0.05).
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Western blot
Astrocytes were transfected with nonspecific control
(siCON) or C/EBPβ-specific (siC/EBPβ) siRNA by
nucleofection and then cultured as adherent monolayers
in 75 cm2 flasks at a density of 8 × 106 cells per flask.
The following day, medium was exchanged with or with-
out IL-1β (20 ng/ml) for 24 h. Alternatively, astrocytes
were cultured in 75 cm2 flasks at a density of 8 × 106
cells per flask for 24 h, and then the medium was
exchanged with or without MAPK-selective inhibitors
(SB203580, U0126; 20 μM) for 1 h and then with inhibi-
tor plus IL-1β (20 ng/ml) for 24 h. Cells were lysed; total
cell extracts were isolated using mammalian protein ex-
traction reagent (Thermo Fisher Scientific, Waltham,
MA, USA). Equal amounts of proteins (15 μg/lane) were
resolved by 12% sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) and subsequently trans-
ferred to a polyvinyl difluoride (PVDF) membrane using
i-Blot (Life Techologies). The membrane was incubated in
anti-C/EBPβ (C-19, Santa Cruz Biotechnology) or anti-
COX-2 (no. 4842, Cell Signaling Inc., Boston, MA, USA) at
a dilution of 1:200. Blots were then incubated in secondary
antibody (1:5,000, Promega Inc., Madison, WI). β-actin
(Sigma-Aldrich Inc., St. Louis, MO, USA) was used as a
loading control. The Western blot was visualized with
supersignal chemiluminescent substrate (Thermo Fisher
Scientific), and band intensities were quantified by densi-
tometry analysis (ProteinSimple, Santa Clara, CA, USA).
Pharmacological inhibitors
Monolayers of astrocytes were treated with 2× the final
dose of the MAPK-selective inhibitors, SB203580 (p38K-
20 μM), SB202190 (p38K-20 μM), U0126 (ERK1/2-20 μM)
and PD184352 (ERK1/2-20 μM) for 1 h before adding equal
volume of 2× the final dose of IL-1β treatment.
Immunocytochemistry
Astrocytes were cultured as adherent monolayers in a 48-
well plate at a density of 0.1×106 cells per well for 24 h,
and then with or without MAPK-selective inhibitors
(SB203580, U0126) for 1 h and then inhibitor plus IL-1β
(20 ng/ml) for 24 h. Experimental cells were fixed with cold
acetone:methanol (1:1) for 30 min at −20 °C. Cells were
then blocked in phosphate-buffered saline (PBS) with 2%
bovine serum albumin (BSA) and 0.1% triton X-100 for 1 h
at room temperature. Cells were incubated in PBS with 2%
BSA and 0.1% triton X-100 plus anti-COX-2 antibody at
1:500 and anti-glial fibrillary acidic protein (GFAP) antibody
at 1:600 for 8 h at 4 °C. Cells were washed with PBS and
then incubated in secondary antibody (1:800) for 1 h at
room temperature. Micrographs were taken on a Nikon
Eclipse Ti. (Nikon Inc., Melville, NY, USA).
Statistical analyses
Statistical analyses were carried out using GraphPad
Prism 5.0 software (GraphPad Software, Inc., La Jolla,
CA), with one-way ANOVA and Newman-Keuls post-
test for multiple comparisons. Data generated from each
assay from the TaqManW Human Inflammation Array (Life
Technologies, C/N: 4414074) were analyzed independently.
Significance was set at p< 0.05, and data represent mean
values±SEM. Data presented are representative of a mini-
mum of three independent experiments with two or more
independent donors, unless noted, in which case, n repre-
sents cumulative data from a specific number of independ-
ent human donors (TaqManW Human Inflammation Array
and western blots).
Results
Human astrocyte IL-1β-induced C/EBPβ, directly or
indirectly, regulates 17 of 29 selected astrocyte
inflammation genes
As previously reported, IL-1β induces astrocyte C/EBPβ ex-
pression and localization to nuclei, where the transcription
factor regulates gene expression [7,17]. Astrogliosis is a
hallmark of many CNS diseases, yet little is known about
how astrocyte C/EBPβ-regulated gene expression may con-
tribute to progression of these pathologies. Here, we used
the TaqManW Human Inflammation Array to evaluate
human astrocyte C/EBPβ’s contribution to expression of 92
inflammatory genes in response to IL-1β. Figure 1 shows
cumulative data from two independent astrocyte donors.
Primary human astrocyte C/EBPβ expression was silenced
using siRNA technology, and cells were cultured in the
presence of IL-1β for 12 h. As Figure 1 indicates, IL-1β
altered mRNA levels of 29 of the 92 genes by two-fold or
greater. C/EBPβ knockdown by siRNA affected expression
of 17 of the 29 genes by 25% or more. Moreover, our data
are supported by previous reports, and we confirmed two
targets in additional donors. Data from previous studies
support our findings that IL-1β-activated astrocytes express
higher levels of NOS-2 and intercellular adhesion molecule
(ICAM)-1, and each was down- and upregulated, respect-
ively, in C/EBPβ-deficient astrocytes [25,26]. Interestingly,
only 4 of the 17 IL-1β-induced genes affected by C/EBPβ
are downregulated in C/EBPβ-deficient astrocytes; the
remaining 13 genes are upregulated. IL-1β induced the ex-
pression of astrocyte prostaglandin endoperoxide synthase
2, or COX-2, mRNA by an average of 824 fold, while C/
EBPβ knockdown in parallel experiments led to an average
of 37% reduction. IL-1β induced the expression of BDKRB2
mRNA by an average of 35 fold; C/EBPβ knockdown fur-
ther enhanced this increase by an average of 68%. These
data suggest that IL-1β-mediated astrocyte C/EBPβ expres-
sion functions to activate or inhibit 17 of 29 of the IL-1β-
induced human astrocyte inflammation genes.
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siRNA knockdown of C/EBPβ affects IL-1β-induced
astrocyte COX-2 and BRKRB2 expression
Differences in genetic background among human astrocyte
donors account for variation in readouts; therefore, we con-
firmed our results for COX-2 and BDKRB2 mRNA in two
additional astrocyte donors. Consistent with our previously
published work [7], a single bolus of IL-1β induced a five-
fold increase in astrocyte C/EBPβ mRNA expression at
12 h and maintained a four-fold increase through 72 h
(Figure 2A; p< 0.001). C/EBPβ-specific siRNA transfection
achieved a 65% knockdown through 72 h in IL-1β-treated
astrocytes (Figure 2A; p< 0.001). We have previously
reported that C/EBPβ-specific siRNA alone reduces basal
levels of C/EBBβ mRNA by 65% [7]. IL-1β induced a 55-
fold increase in astrocyte BDKRB2 mRNA expression at
12 h and maintained increases of 45- (24 h) and 40-fold
(72 h) (Figure 2B; p< 0.001). C/EBPβ-deficient astrocytes
expressed BDKRB2 mRNA levels at 83 (12 h), 65 (24 h)
and 60 fold (72 h) that of control siRNA (siCON)-trans-
fected astrocytes (Figure 2B, p< 0.001). IL-1β induced 700-
(12 h), 533- (24 h) and 400-fold (72 h) increases in astrocyte
COX-2 mRNA expression, while C/EBPβ knockdown
downregulated this robust induction by 26% (12 h), 39%
(24 h) and 31% (72 h) (Figure 2C, p< 0.001). These data
confirm the mRNA expression results from the TaqManW
Human Inflammation Array plate.
Next, we investigated the changes in COX-2 expre-
ssion by immunoblot analyses in the context of C/EBPβ-
specific siRNA transfection followed by IL-1β activation.
To confirm siC/EBPβ effectively blocked IL-1β-induced
astrocyte C/EBPβ, we performed immunoblot analysis of
24 h protein lysates; results from 72-h lysates were previ-
ously reported [7]. IL-1β induced astrocyte C/EBPβ protein
expression at 24 h post-treatment; however, transfection
with siC/EBPβ reduced these levels (Figure 3A). Densito-
metry analysis of two independent donors indicates C/EBPβ
levels are significantly reduced in siC/EBPβ-transfected
astrocytes (Figure 3B, p< 0.001). IL-1β induced astrocyte
COX-2 protein expression at 24 h post-treatment
(Figure 3C). IL-1β-induced astrocyte COX-2 was decreased
in siC/EBPβ-transfected cells compared to siCON-
transfected cells. Densitometry analyses showed signifi-
cantly more COX-2 protein was expressed in IL-1β-treated
astrocytes compared to untreated cells (p< 0.01); however,
siC/EBPβ-transfected cells expressed reduced COX-2 com-
pared to siCON-transfected cells (Figure 3D, p< 0.05).
These data suggest that C/EBPβ regulates mRNA and pro-
tein expression of multiple human astrocyte inflammation
genes.
Differential roles of p38K and ERK1/2 signaling pathways
in astrocyte COX-2 and BDKRB2 regulation
IL-1β activates a cascade of signal transduction molecules
to regulate astrocyte gene expression. Recent studies
suggest that IL-1β signals through the p38K pathway to ac-
tivate C/EBPβ [21]. To determine if a common pathway
regulates C/EBPβ and COX-2, and/or if an alternate path-
way regulates BDKRB2, astrocytes were treated with
Figure 2 C/EBPβ knockdown enhances BDKRB2 and reduces
COX-2 mRNA. Astrocytes were transfected with siRNA specific for
C/EBPβ or siCON (100 nM), and then cultured for 24 h before being
treated with IL-1β (20 ng/ml) for 12, 24 or 72 h. Total RNA was
isolated, reverse-transcribed and then assayed by RT2PCR for (A) C/
EBPβ, (B) BDKRB2 and (C) COX-2 relative transcripts levels. GAPDH
was used as the normalizing control; p-values are compared to
control unless denoted by lines to specific comparisons.
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SB203580 or U0126, and then with IL-1β for 12 h. Con-
sistent with data from the two donors used for the array
plate (Figure 1), IL-1β induced a 30-fold increase in
BDKRB2 mRNA compared to untreated cells (Figure 4A,
p< 0.001); pretreating the cells with SB203580 had no sig-
nificant effect on BDKRB2 mRNA levels compared to IL-
1β alone. However, pretreating astrocytes with U0126 sig-
nificantly reduced the IL-1β-mediated increase in BDKRB2
mRNA by 75% (Figure 4A, p< 0.001). IL-1β induced a
600-fold increase in COX-2 mRNA compared to untreated
cells (p< 0.001); SB203580 pretreatment reduced this re-
sponse by 93% (Figure 4B, p< 0.001). IL-1β induced a
1,400-fold increase in COX-2 mRNA in U0126-pretreated
astrocytes; this was a significant increase compared to
astrocytes treated with IL-1β alone (Figure 4B, p< 0.001).
Similar results were obtained using the p38K- and ERK1/2-
selective inhibitors SB202190 and PD184352, respectively
(Additional file 1). Moreover, these data suggest that the
p38K and ERK1/2 pathways are essential for IL-1β-
mediated increases in COX-2 and BDKRB2 expression,
respectively.
To confirm that changes in COX-2 and BDKRB2
mRNA lead to changes in protein levels, we pretreated
astrocytes with SB203580 or U0126, and then with IL-1β
for 24 h. Western blot analysis results were consistent
with the mRNA expression studies. COX-2 (70 kDa) was
undetectable in total protein lysates from untreated
astrocytes; however, a 70-kDa isoform was detected in
lysates from IL-1β-treated astrocytes (Figure 5A). The
COX-2 signal was undetectable in lysates from SB20380-
pretreated astrocytes compared with IL-1β alone
(Figure 5A). The COX-2 signal was more intense in
lysates from U0126-pretreated astrocytes compared to
all other conditions (Figure 5A). Densitometry analyses
of the bands revealed higher COX-2 levels in IL-1β-
treated astrocytes; however, SB203580 pretreatment
blocked this increase (Figure 5B). Significantly more
COX-2 was detected from lysates of U0126-pretreated
astrocytes compared to untreated and SB203580/IL-1β-
treated astrocytes (p< 0.05; Figure 5B).
To determine if blocking p38K or ERK1/2 activity
affects IL-1β-mediated COX-2 cellular localization, we
pretreated astrocytes with selective inhibitors and then
with IL-1β for 24 h, fixed and colocalized GFAP as an
astrocyte-specific marker (green) with COX-2 (red,
Figure 6A-D) in human astrocytes. The cell body of con-
trol cells is large, and the processes are wide
(Figure 6A). The processes of activated astrocytes are
Figure 3 C/EBPβ knockdown blocks IL-1β-induced C/EBPβ and COX-2 protein levels. Astrocytes were transfected with siRNA specific for C/
EBPβ or siCON (100 nM) and then cultured for 24 h before being treated with IL-1β (20 ng/ml) for 24 h. (A and C) Protein lysates were isolated,
resolved by SDS-PAGE, transferred to a PVDF membrane and then immunoblotted for C/EBPβ and COX-2 expression. (B and D) The densitometry
graph is cumulative data from two independent astrocyte donors (n= 2) that were normalized to β-actin (B and D); p-values are compared to
control unless denoted by lines to specific comparisons.
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more condensed, and staining of GFAP is more intense
(Figure 6B-D). Low levels of COX-2 are detected in con-
trol human astrocytes (Figure 6A) compared with acti-
vated astrocytes, where the red signal throughout the
cell is enhanced (Figure 6B). Together with the previ-
ously shown mRNA and protein expression data, this
confirms that COX-2 expression is increased in astro-
cytes (Figures 2, 3, 4 and 5). Low levels of COX-2 are
detected in SB203580-pretreated astrocytes compared to
those treated with IL-1β alone (Figure 6C), while the
COX-2 signal is enhanced in U0126-pretreated astro-
cytes (Figure 6D). These data illustrate that SB203580
blocks IL-1β-mediated COX-2 expression, whereas,
U0126 enhances IL-1β-mediated COX-2 expression.
Discussion
Astrocytes are multifunctional glial cells that maintain
CNS homeostasis, neuronal signaling, BBB and
responses to trauma. Neuroinflammation is a contribu-
ting factor of many CNS diseases and profoundly affects
astrocyte gene expression [1,27]. Immune-induced
Figure 4 IL-1β signals through ERK1/2 and p38K to increase astrocyte BDKRB2 and COX-2 mRNA, respectively. Astrocytes were cultured
for 24 h, pretreated with pathway-selective inhibitors (20 μM) and then treated with IL-1β for 12 h. Total RNA was isolated, reverse-transcribed
and then assayed by RT2PCR for (A) BDKRB2 or (B) COX-2 relative transcript levels. GAPDH was used as the normalizing control; p-values are
compared to control unless denoted by lines to specific comparisons.
Figure 5 IL-1β signals through p38K to increase astrocyte COX-
2 protein. (A-B) Astrocytes were cultured for 24 h, pretreated with
pathway-selective inhibitors (SB203580-20 μM and U0126-20 μM)
and then treated with IL-1β for 24 h. Total protein lysates were
isolated, resolved by SDS-PAGE, transferred to a PVDF membrane
and then immunoblotted for COX-2 expression. (B) COX-2 and β-
actin bands were analyzed by densitometry analysis, and their
intensities graphed using β-actin as the loading control; p-values are
compared to control unless denoted by lines to specific
comparisons. Densitometry fold change data are cumulative from
two independent astrocyte donors (n= 2).
Figure 6 p38K-selective small molecule inhibitor blocks IL-1β-
induced COX-2 expression. (A-D) Astrocytes were cultured in 48-
well plates for 24 h, treated with selective inhibitors (SB203580-
20 μM, and U0126-20 μM) for 1 h and then IL-1β (20 ng/ml) for
24 h. Cells were fixed, blocked and then incubated with antibodies
against GFAP (green) and COX-2 (red). All pictures were taken at
×200, and data represent at least three independent experiments in
at least two independent donors.
Fields and Ghorpade Journal of Neuroinflammation 2012, 9:177 Page 7 of 11
http://www.jneuroinflammation.com/content/9/1/177
changes in astrocyte gene expression are well documen-
ted and play an important role in restoring normal CNS
function after trauma [1,28]. Currently, investigators lack
a full understanding of how astrocytes contribute to the
initiation and control of CNS immune responses. To this
end, we sought to characterize the role of C/EBPβ in
regulating IL-1β-mediated increases in primary human
astrocyte expression of a panel of inflammatory genes.
Here, we used an array of 92 human inflammatory genes
to assay the effect of IL-1β on expression of these genes
in two independent human astrocytes donors. Expre-
ssion of 29 of the 92 mRNAs was affected by at least
two fold, and C/EBPβ knockdown affected expression of
17 of the 29 genes by at least 25%. We confirmed IL-1β-
mediated COX-2 and BDKRB2 expression, with and
without C/EBPβ knockdown. C/EBPβ knockdown
decreased COX-2 mRNA and protein levels, while it
increased BDKRB2 mRNA expression. Data from a
related study show p38K inhibition blocks IL-1β-
mediated astrocyte C/EBPβ expression, whereas ERK1/2
inhibition enhances expression [8]. Accordingly, we
found that the IL-1β-mediated increase in COX-2
expression is p38K-dependent, whereas IL-1β-mediated
expression of BDKRB2 is ERK1/2-dependent. Interes-
tingly, ERK1/2 pathway inhibition exacerbated IL-1β-
mediated COX-2 induction. On the contrary, BDKRB2
induction by IL-1β was robustly diminished with ERK1/
2 inhibition. Lastly, data showed that IL-1β signals
through the p38K pathway to increase expression of
COX-2. Our data show that C/EBPβ, in concert with
other factors, may contribute to regulation of many
human astrocyte genes during neuroinflammation.
Advances in gene expression technology have facilitated
the study of astrocytes in disease processes. Genomic array
data of IL-1β-induced astrocyte gene expression studies
were compiled and thoroughly reviewed by John et al.
(2005); several of our data are corroborated therein. As in
this report, multiple arrays have shown IL-1β induces
CD40, NOS-2, vascular cell adhesion molecule-1, ICAM-1,
TNF and COX-2 [29,30]. Other studies have utilized more
diverse stimuli to study immune-induced astrocyte gene ex-
pression, such as interferon, HIV-1 virion particles or viral
proteins [29,30]. Interestingly, HIV-1-treated murine astro-
cytes increase expression of many of these same genes:
CD40, COX-2 and TIMP-1 [30]. Overall, the results of this
study corroborate those of past studies while adding critical
regulators of neuroinflammation and BBB integrity, such as
BDKRB2, to the list of IL-1β-induced human astrocyte
genes.
C/EBPβ expression is detectable in immune-activated ro-
dent glia, and it is now clear that this factor is involved in
inflammatory processes in tissues throughout the body
[17,31]. In the brain, data suggest that C/EBPβ is a direct
downstream target of neural growth factor during
neurogenesis [32]. C/EBPβ activates regeneration-
associated gene expression following axon injury and pro-
vides cerebral protection to excitotoxic injury in mouse
brains [33–35]. Our group recently reported that C/EBPβ
is detectable in brains of HIV-1-infected patients and the
factor contributes to regulating IL-1β-mediated astrocyte
TIMP-1 [7]. C/EBPβ regulates IL-1β-mediated human
astrocyte C3 expression [21], but more in-depth studies on
human astrocytes are lacking [20,21]. Here, we found that
the majority of IL-1β-induced transcript levels were affected
by C/EBPβ knockdown. Studies have shown that all three
isoforms can function as repressors of transcription [16]. C/
EBPβ binds with C/EBPδ, nuclear factor (NF)κB and activa-
tor protein-1 (AP-1) in various cell types to affect gene ex-
pression [36]. NFκB is a key factor in IL-1β-induced gene
expression; however, varying combinations of transcrip-
tion factors may determine how transcription is affected
at each promoter. Furthermore, posttranslational modifi-
cations can affect transcription factor function; ERK1/2-
mediated phosphorylation or sumoylation represses C/
EBPβ transcription [16,37]. Therefore, manipulating C/
EBPβ expression levels alone may have limited effect.
Conversely, overexpression or repression of multiple fac-
tors or mutations that alter their posttranslational modifi-
cations may provide a route to modify gene expression in
a highly specific manner. To this end, researchers must
identify the proportion, and derivatives of the various im-
portant factors (NFκB, C/EBPβ, C/EBPδ and AP-1), and
then manipulate them in a way that results in therapeutic
changes in gene expression. Such drug formulations
would have the potential to limit side effects while maxi-
mizing potency. Here, C/EBPβ knockdown increased ex-
pression of 13 of 17 transcripts tested.
As previously reported, NOS-2 and ICAM-1 expression
levels were negatively and positively affected by C/EBPβ
knockdown, respectively [15,19]. Of the four mRNA levels
decreased in siC/EBPβ-transfected astrocytes, we first chose
to focus on COX-2, the most highly induced gene that was
affected by C/EBPβ knockdown. COX-2 is an enzyme that
converts arachidonic acid to prostaglandin endoperoxide
H2. COX-2 enzyme is a key player during inflammation
and therapeutic target of non-steroidal anti-inflammatory
drugs. C/EBPβ affects COX-2 expression in a cell-
dependent manner; supporting the notion that multiple
factors and the derivatives thereof ultimately determine
gene expression in any given cell type [16,36]. The regula-
tion of COX-2 via C/EBPβ is thus highly significant both
from the perspective of understanding inflammation as
well as therapeutic approaches. C/EBPβ, C/EBPδ, NFκB,
cyclic adenosine monophosphate response element-
binding protein and AP-1 all regulate COX-2 expression
in various cell types [15,38]. C/EBPβ is essential for rodent
macrophage biphasic expression of COX-2; however, in
A431 cells, all C/EBPβ isoforms repress COX-2 expression,
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whereas fibroblast COX-2 expression is not C/EBPβ-
dependent [16,36,39]. These data suggest that the highly in-
ducible COX-2 may be regulated in a cell-specific manner
to respond to inflammatory stimuli. In our studies, IL-1β
induced robust increases in human astrocyte COX-2 ex-
pression; COX-2 was the second most induced gene among
all donors tested. Additionally, p38K signaling and C/EBPβ
expression may be crucial for astrocyte COX-2 expression
during neuroinflammation. In murine macrophages, IL-1β
signals through ERK1/2 to increase COX-2 expression
[36]. In our studies, an ERK1/2-selective inhibitor
increased IL-1β-mediated human astrocyte C/EBPβ and
COX-2 expression [7]. MAPK pathway activity is impli-
cated in many disease processes, and therefore, pathway-
selective inhibitors are being tested as effective therapies
[40]. The current studies illustrate why these pharmaco-
logical inhibitors may represent a “blunt-ended” tool when
trying to affect expression-specific genes. Blocking a spe-
cific pathway or even transcription factor can have pro-
found effects; however, manipulating multiple factors in
specific ways may allow fine-tuning of gene expression.
These data suggest that the ERK1/2 pathway may activate
inhibitors of C/EBPβ and thereby inhibit COX-2
expression. Indeed, ERK1/2 is capable of phosphorylating
and thereby repressing C/EBPβ activity [37].
C/EBPβ knockdown increased IL-1β-induced astrocyte
BDKRB1 and BDKRB2 expression as well as that of 11
other genes (Figure 1). We chose to further investigate
BDKRB2 expression because of the key role the
kallikrein-kinin system plays in the CNS [41]. Most of
the biological effects of the kinin system are mediated
through BDKRB2 [41]. Interestingly, BDKRB2 signaling
mediates prostaglandin release [42]; collectively, these data
suggest that C/EBPβ may play a key role in modulating the
inflammatory response by effectively decreasing BDKRB2
signaling (through downregulation of mRNA) while
concomitantly increasing COX-2 expression. These data
bolster the assertion that transcription factors may func-
tion in a context-dependent manner, possibly even within
a single cell. Data suggest BDKRB2 signaling may increase
BBB permeability [43–46]; an important function during
CNS immune responses [47]. Our group is particularly
interested in the progression of HAD, and BBB permeabi-
lity is a contributing factor to HIV-1 entering the CNS
[48,49]. IL-1β induced a robust increase in human astrocyte
BDKRB2 mRNA expression, and C/EBPβ knockdown
Figure 7 IL-1β activates astrocyte MAPK pathways, activates transcription factors and thereby regulates multiple human inflammation
genes. IL-1β-mediated activation of astrocyte MAPK [p38K and ERK1/2] pathways precedes robust changes in gene expression. Multiple
transcription factors traffic to astrocyte nuclei where they facilitate changes in mRNA transcription. Blocking IL-1β-mediated activation of astrocyte
p38K blocks C/EBPβ translocation to nuclei [8]. The subsequent effects are similar to C/EBPβ knockdown; IL-1β-induced astrocyte TIMP-1 and
COX-2 expression is blocked, and BDKRB2 expression is enhanced (Figure 4) [8]. ERK1/2 inhibition completely blocks IL-1β-induced astrocyte
BDKRB2 expression and TIMP-1 expression, but enhances IL-1β-induced C/EBPβ and COX-2 expression (Figures 4, 5 and 6) [8]. Two scenarios
involving C/EBPβ could explain these events: (1) Blocking ERK1/2 signaling inhibits factors essential for IL-1β-induced astrocyte TIMP-1 expression
and results in increased C/EBPβ translocation to nuclei to compensate for reduced TIMP-1 transcription. Increased C/EBPβ may account for
increased COX-2. (2) Alternatively, ERK1/2 signaling may directly down-modulate IL-1β-induced astrocyte C/EBPβ; therefore, ERK1/2-selective
inhibitors may increase COX-2 through an increase in CEBPβ activity. In either scenario, ERK1/2 is essential, and C/EBPβ is an auxiliary path to IL-
1β-induced astrocyte TIMP-1. These data suggest MAPK, p38K and ERK1/2 are part of an intricate regulation network in which the two kinases
balance one another’s activity to achieve a graded astrocyte response to CNS injury.
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consistently enhanced this effect. Furthermore, ERK1/2 sig-
naling is critical for IL-1β-mediated astrocyte BDKRB2 ex-
pression. The p38K-selective inhibitor showed an increase,
but no significant effect on BDKRB2 mRNA levels. These
signaling data further support complementary regulation of
astrocyte COX-2 and BDKRB2 at the level of transcription
factors and signal transduction. These data may lead to
novel mechanisms to manipulate prostaglandin production
and affect inflammation in tissue microenvironments.
Conclusions
Overall, with the data in the current study and other on-
going investigations, we shed some light on the complex
nature of astrocyte gene regulation during neuroinflam-
mation. Astrocyte C/EBPβ, TIMP-1, COX-2 and
BDKRB2 regulation show that p38K and ERK1/2 may
differentially regulate multiple genes in a graded manner.
Furthermore, C/EBPβ may act to repress some ERK1/2-
regulated genes and activate p38K-regulated genes while
acting in a more auxiliary role regulating genes such as
TIMP-1 (Figure 7). As with all expression array read-
outs, the gene targets need to be individually confirmed
in vitro, in vivo and then in disease. Nonetheless, in
addition to identifying new genes affected by C/EBPβ
knockdown, this work illustrates the complexity of astro-
cyte gene regulation and the need to outline species-
and cell-type-specific regulation of important inflamma-
tory mediators. Our findings help to identify and under-
stand the transcriptome of factors that mediate human
astrocyte inflammatory response. Identifying the other
factors that join with C/EBPβ to regulate human astro-
cyte inflammatory responses may provide new thera-
peutic targets for ameliorating CNS pathology.
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